Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Biogen and Denali Therapeutics announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease failed to meet its primary or secondary endpoints. The drug did not slow disease progression versus placebo, leading the companies to discontinue development of BIIB122 in idiopathic Parkinson’s disease.
Key figures
- Drug Name
- BIIB122 (DNL151)
- Phase Of Trial
- Phase 2b
- Study name
- LUMA
- Patient count
- 648
- Kinase inhibition
- >90%
- Biomarker reduction
- ~30%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.